Monopar joins Russell 3000 and 2000 indexes, growth acknowledged

WILMETTE, Ill. - Monopar Therapeutics Inc. (NASDAQ:MNPR), a biopharmaceutical company specializing in treatments for unmet medical needs with a market capitalization of $183.5 million, will be added to the Russell 3000 Index and consequently the Russell 2000 Index after U.S. equity markets close on June 27, 2025. The company’s stock has shown remarkable strength, delivering a 680% return over the past year according to InvestingPro data. This inclusion, announced today, follows the preliminary notification on May 23 and an update on May 30, 2025, as part of the Russell U.S. Indexes annual reconstitution.

The Russell 2000 Index, which is a subset of the Russell 3000 Index, is designed to track the performance of the small-cap segment of the U.S. equity market. Inclusion in these indexes is seen as a recognition of Monopar’s growth, particularly in light of the development of its late-stage drug candidate ALXN1840 for Wilson disease. Analysts maintain an optimistic outlook, with price targets ranging from $40 to $76, suggesting significant upside potential. InvestingPro subscribers can access 8 additional key insights about MNPR’s financial health and growth prospects. Quan Vu, Monopar’s Chief Financial Officer, expressed the company’s honor in joining the Russell indexes and attributed the achievement to the recognition of their drug candidate’s potential.

FTSE Russell, which provides the Russell U.S. Indexes, is a global leader in index and data solutions. These indexes are widely used by investment managers and institutional investors for benchmarking both active and passive investment strategies. As of May 2025, around $10.6 trillion in assets are benchmarked against these indexes.

Monopar Therapeutics is currently involved in various stages of drug development, including their radiopharmaceutical programs for imaging and treating advanced cancers. The company’s inclusion in the Russell indexes is effective for one year until the next reconstitution. With a strong current ratio of 36.92 and more cash than debt on its balance sheet, the company appears well-positioned to fund its development programs.

The company’s forward-looking statements indicate plans to initiate regulatory processes for ALXN1840 and outline the risks and uncertainties inherent in the development and commercialization of new pharmaceutical products. Monopar Therapeutics has stated its intention to continue raising funds to support its clinical, regulatory, and commercial endeavors.

This news is based on a press release statement and reflects the company’s position as of today. Monopar Therapeutics has emphasized that the views expressed in the press release are current as of its date and may change in the future.

In other recent news, Monopar Therapeutics announced its fourth quarter and full-year 2024 financial results, prompting Jones Trading to downgrade the company’s stock from a Buy to a Hold rating. The downgrade reflects a recalibration of expectations, with analysts noting that Monopar’s current market valuation adequately reflects its prospects until more progress is made towards a new drug application for ALXN-1840. Meanwhile, Piper Sandler initiated coverage of Monopar with an Overweight rating and set a price target of $76 per share, highlighting optimism about the potential of ALXN1840 for Wilson disease. Piper Sandler’s analysis is based on Phase 3 trial data, suggesting a high chance of FDA approval due to the unmet medical need for this condition. Additionally, Monopar announced the appointment of Quan Vu as the new Chief Financial Officer, succeeding Karthik Radhakrishnan. Vu brings extensive experience in corporate and financial strategy, having held various leadership roles in the pharmaceutical industry. This executive change is part of Monopar’s ongoing efforts to strengthen its strategic direction. Monopar’s development of therapies targeting uPAR for solid tumors is seen as a potential upside for future growth, according to Piper Sandler.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.